Abstract | OBJECTIVE: METHODS: Thirty four children and adolescents with type 1 DM (mean age 12.7 ± 3.4 years, diabetes duration 5.4 ± 3.0 years) were included in the study. All patients had been receiving intensive insulin therapy with insulin aspart and NPH for at least 6 months before switching from NPH to insulin glargine (Group 1, n=19) or detemir (Group 2, n=15). The medical records obtained within 6 months before and after treatment with insulin glargine and detemir were retrospectively reviewed and the data were compared in each group. RESULTS: The mean age and duration of DM were similar in two groups (p>0.05). In both groups, switching from NPH to insulin glargine or detemir, resulted in a reduction in HbA(1c) (p0.05, for both). Patients in the detemir treated group had less increment in body mass index (BMI) SDS at the end of 6 months of therapy compared to NPH and glargine treated patients (p>0.05, for both). No side effects were noted throughout the study. CONCLUSION: Both insulin glargine and detemir improved HbA(1c) at short-term and proved to be safe and well tolerated in children and adolescents with type 1 DM.
|
Authors | Bumin Nuri Dündar, Nihal Dündar, Erdal Eren |
Journal | Journal of clinical research in pediatric endocrinology
(J Clin Res Pediatr Endocrinol)
Vol. 1
Issue 4
Pg. 181-7
( 2009)
ISSN: 1308-5735 [Electronic] Turkey |
PMID | 21274293
(Publication Type: Clinical Trial, Comparative Study, Journal Article)
|
Chemical References |
- Blood Glucose
- Glycated Hemoglobin A
- Hypoglycemic Agents
- Insulin, Long-Acting
- hemoglobin A1c protein, human
- Insulin Glargine
- Insulin Detemir
- Insulin, Isophane
|
Topics |
- Adolescent
- Blood Glucose
(metabolism)
- Body Mass Index
- Child
- Diabetes Mellitus, Type 1
(blood, drug therapy, pathology)
- Female
- Glycated Hemoglobin
(metabolism)
- Humans
- Hypoglycemic Agents
(adverse effects, therapeutic use)
- Insulin Detemir
- Insulin Glargine
- Insulin, Isophane
(adverse effects, therapeutic use)
- Insulin, Long-Acting
(adverse effects, therapeutic use)
- Male
- Retrospective Studies
- Treatment Outcome
|